doi:10.3969/j.issn.1673-8640.2019.11.019

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 12

[1]	袁腾飞,李艳,彭锐. 人附睾蛋白4对慢性肾脏病的诊断价值[J]. 检验医学与临床,2017,14(5):599-600.
[2]	田瑞,周芸. 慢性肾脏病概念及分期诊断标准的演变和现状[J]. 国际移植与血液净化杂志,2018,16(1):1-4.
[3]	全国eGFR课题协作组. MDRD方程在我国慢性肾脏病患者中的改良和评估[J]. 中华肾脏病杂志,2006,22(10):589-595.
[4]	LIU L,NING X,BAI M,et al.Prognostic and diagnostic value of HE4 expression in patients with chronic kidney diseases[J]. Int J Clin Exp Pathol,2016,9(8):7930-7940.
[5]	王莲子,李涛. 人附睾蛋白4检测及其临床诊断应用的研究进展[J]. 临床检验杂志,2018,36(7):517-519.
[6]	桑国耀,胡金伟,张朝霞. 血清HE4在慢性肾脏疾病分期中的诊断价值[J]. 标记免疫分析与临床,2019,26(1):40-43.
[7]	吴萍,叶伟民,李晨,等. 人附睾蛋白4对慢性肾脏疾病的诊断价值研究[J]. 检验医学,2015,30(5):461-464.
[8]	李婷娜,董振芳,鞠瑛,等. 人附睾蛋白4在肺癌中的临床应用诊断价值探讨[J]. 国际呼吸杂志,2018,38(4):252-255.
[9]	高海锋,田华,赵秋剑. 血清人附睾蛋白4、糖类抗原125检测联合卵巢恶性肿瘤风险评估指数对卵巢癌的诊断价值[J]. 肿瘤研究与临床,2018,30(11):757-761.
[10]	武炜,段巧艳,刘小军. 血清HE4及CA 125在慢性肾脏疾病中的诊断价值[J]. 中国临床实用医学,2017,8(2):48-52.
[11]	施洪耀,温东华,范成辉. 人附睾蛋白4在慢性心力衰竭患者诊断及治疗效果评估中的应用价值[J]. 临床内科杂志,2018,35(4):258-260.
[12]	WAN J,WANG Y,CAI G,et al.Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease[J]. Oncotarget,2016,7(42):67748-67759.

组别	例数	HE4（pmol/L）	Cr（mol/L）	Cys C（mg/L）	β₂-MG（mg/L）	尿素（mmol/L）
CKD组	120	467.15±43.65	218.0±92.9	3.6±2.5	11.2±9.5	14.18±7.45^*
Ⅰ期	40	113.6±50.8^*	55.5±14.9	1.3±0.3^*	3.0±1.3^*	12.6±11.0^*
Ⅱ期	30	210.1±94.0^*#	94.1±35.7^*#	1.4±0.4^*#	3.8±1.4^*	12.3±11.5^*
Ⅲ期	23	286.3±171.5^*#△	135.7±53.8^*#△	2.2±1.1^*#△	7.6±3.7^*#△	15.0±12.2^*#△
Ⅳ期	18	483.8±333.3^*#△▲	221.3±98.9^*#△▲	3.7±2.3^*#△▲	8.8±3.1^*#△▲	15.3±13.6^*#△
Ⅴ期	9	899.2±437.4^*#△▲□	490.5±210.5^*#△▲□	4.5±1.4^*#△▲□	18.6±9.3^*#△▲□	28.6±14.9^*#△▲□
正常对照组	120	55.7±7.5	54.0±5.4	0.7±0.2	0.6±0.2	5.1±3.1

组别	例数	HE4（pmol/L）	Cr（mol/L）	Cys C（mg/L）	β₂-MG（mg/L）	尿素（mmol/L）
CKD组	120	467.15±43.65	218.0±92.9	3.6±2.5	11.2±9.5	14.18±7.45^*
Ⅰ期	40	113.6±50.8^*	55.5±14.9	1.3±0.3^*	3.0±1.3^*	12.6±11.0^*
Ⅱ期	30	210.1±94.0^*#	94.1±35.7^*#	1.4±0.4^*#	3.8±1.4^*	12.3±11.5^*
Ⅲ期	23	286.3±171.5^*#△	135.7±53.8^*#△	2.2±1.1^*#△	7.6±3.7^*#△	15.0±12.2^*#△
Ⅳ期	18	483.8±333.3^*#△▲	221.3±98.9^*#△▲	3.7±2.3^*#△▲	8.8±3.1^*#△▲	15.3±13.6^*#△
Ⅴ期	9	899.2±437.4^*#△▲□	490.5±210.5^*#△▲□	4.5±1.4^*#△▲□	18.6±9.3^*#△▲□	28.6±14.9^*#△▲□
正常对照组	120	55.7±7.5	54.0±5.4	0.7±0.2	0.6±0.2	5.1±3.1

项目	AUC（95% 可信区间）	最佳临界值	敏感性（%）	特异性（%）
HE4	0.95（0.91~0.98）	233.58 pmol/L	95.9	98.7
Cr	0.96（0.92~0.99）	68.20 μmol/L	97.5	98.6
Cys C	0.95（0.92~0.98）	2.90 mg/L	95.2	99.9
β₂-MG	0.93（0.90~0.98）	5.35 mg/L	89.3	98.7
尿素	0.78（0.67~0.80）	10.71 mmol/L	71.5	95.6

项目	AUC（95% 可信区间）	最佳临界值	敏感性（%）	特异性（%）
HE4	0.95（0.91~0.98）	233.58 pmol/L	95.9	98.7
Cr	0.96（0.92~0.99）	68.20 μmol/L	97.5	98.6
Cys C	0.95（0.92~0.98）	2.90 mg/L	95.2	99.9
β₂-MG	0.93（0.90~0.98）	5.35 mg/L	89.3	98.7
尿素	0.78（0.67~0.80）	10.71 mmol/L	71.5	95.6

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 12

Related Articles 15

Recommended Articles

Metrics